ALTERITY THERAPEUTICS LIMITED (ATH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ATH

ATH - ALTERITY THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.01

30 Apr
2026

0.000

OPEN

$0.01

0.000

HIGH

$0.01

12,036,713

LOW

$0.01

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-0.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx0.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.5 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-43.23 %
Return on Invested Capital xxxxxxxxxxxxxxx-43.12 %
Return on Assets xxxxxxxxxxxxxxx-37.23 %
Return on Equity xxxxxxxxxxxxxxx-43.23 %
Return on Total Capital xxxxxxxxxxxxxxx-70.82 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx41 M
Price To Book Value xxxxxxxxxxxxxxx2.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx14 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

29/04/2026

1

Speculative Buy

$0.016

60.00%

Canaccord Genuity highlights recent positive developments for Alterity Therapeutics. The FDA has confirmed no major changes are required to the company's chemistry, manufacturing and control (CMC) plans for ATH434.

ATH434 is an oral small molecule designed to treat multiple system atrophy.

The FDA confirmation is seen as supporting timelines for an end-of-Phase II meeting in mid-2026, with manufacturing scale-up progressing in parallel.

The broker also notes encouraging data presented at the American Academy of Neurology, supporting ATH434's treatment effect.

Commentary suggests development of the MuSyCA outcome measure may provide more robust clinical endpoints, reinforcing confidence in the drug's potential.

Canaccord retains a Speculative Buy rating and target of 1.6c.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.20 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.30 cents.
Access Extra Coverage Research History >

ATH STOCK CHART

FNArena News on ATH

4
Class of 2020

Jul 09 2020 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest